Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2020-03-12 / Front Oncol 2020;10:343New Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2020-03-06 / Biomedicines 2020 Mar;8(3)Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting
/in Dendritic Cells, International Publications /von 2020-03-05 / Cancers (Basel) 2020 Mar;12(3)Dendritic cell vaccine for the effective immunotherapy of breast cancer
/in Breast Cancer, Dendritic Cells, International Publications /von 2020-03-04 / Biomed. Pharmacother. 2020 Jun;126:110046Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial
/in Acute Leukemia, Dendritic Cells, International Publications /von 2020-03-03 / Clin Transl Immunology 2020;9(3):e1117T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2020-03-01 / J Immunother Cancer 2020 Mar;8(1)Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
/in Dendritic Cells, Immunogenic Cell Death, International Publications, Newcastle Disease Virus, Prostate Cancer /von 2020-03-01 / J Immunother Cancer 2020 03;8(1)Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2020-02-27 / Cancers (Basel) 2020 Feb;12(3)Immunotherapy in Malignant Pleural Mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2020-02-21 / Front Oncol 2020;10:187
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de